Gossamer Bio

Gossamer Bio FCF/Net Income

The Free Cash Flow to Net Income Ratio of Gossamer Bio (GOSS) as of Nov 20, 2026 is 100.57 %. In the previous year, Free Cash Flow to Net Income Ratio was 6.14 % — a change of 1,539.32% (higher).

FCF/Net Income

100.57 %

YoY

1,539.32%

Last updated:

Free Cash Flow to Net Income Ratio of Gossamer Bio is 2025 100.57 % . Free Cash Flow to Net Income Ratio of Gossamer Bio was 2024 6.14 % . It decreases by 1,539.32% higher compared to the previous year.

The Gossamer Bio FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2018
49.16 USD
Jan 1, 2019
83.73 USD
Jan 1, 2020
82.69 USD
Jan 1, 2021
81.41 USD
Jan 1, 2022
81.75 USD
Jan 1, 2023
88.51 USD
Jan 1, 2024
6.14 USD
Jan 1, 2025
100.57 USD
The Gossamer Bio FCF/Net Income history
YEARFCF/Net IncomeYoY
100.57 %+1,539.32%
6.14 %-93.07%
88.51 %+8.28%
81.75 %+0.41%
81.41 %-1.55%
82.69 %-1.24%
83.73 %+70.31%
49.16 %-63.95%
136.39 %-96.74%
4,180.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Gossamer Bio Stock analysis

What does Gossamer Bio do? The company Gossamer Bio Inc. was founded in 2015 by Faheem Hasnain and Sheila Gujrathi. The founders had previously worked at various biotechnology companies and now wanted to start their own company to develop innovative products in the field of immunology. Gossamer Bio is headquartered in San Diego, California and currently employs around 200 people. The company specializes in researching and developing therapeutics for a wide range of diseases, including respiratory diseases, cancer, immunological disorders, and infections. Gossamer Bio's business model is based on identifying promising new drug candidates and subsequently developing therapeutics that have the potential to improve patients' lives. Key pillars of the business model include partnerships with established companies and investors, as well as the rapid and efficient conduct of clinical trials. Gossamer Bio's portfolio includes various pipeline programs in different stages of development. An important focus is on the development of new drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). A promising drug candidate in this area is GB001, an inhalation medication that aims to reduce inflammation in the airways. Another important program of Gossamer Bio is the development of therapeutics for the treatment of cancer. The company focuses on the development of drugs that target the body's immune system to specifically fight tumor cells. A promising drug candidate in this area is GB1275, an antibody that specifically targets a protein overexpressed by some types of cancer. In addition to these two focus areas, Gossamer Bio also has programs in the development of therapeutics for the treatment of immunological disorders such as inflammatory bowel disease and rheumatoid arthritis, as well as for the treatment of infections such as COVID-19. Overall, Gossamer Bio has a wide range of promising drug candidates that have the potential to revolutionize the field of immunology and disease management. The company is well positioned to make significant progress in the development of new therapeutics in the coming years and improve the lives of millions of patients worldwide. Gossamer Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gossamer Bio stock

Free Cash Flow to Net Income Ratio of Gossamer Bio is 100.57 % in 2025.

Free Cash Flow to Net Income Ratio of Gossamer Bio changed from 6.14 % to 100.57 %, representing a 1,539.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio Gossamer Bio since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's Gossamer Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Gossamer Bio

All Key Metrics — Gossamer Bio